🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522331-34-00
Authorised Phase I

A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144

2025-522331-34-00 · tracked via the Priya Life Science EU tracker
Sponsor
Pfizer Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
09/09/2025
Enrollment target
12
Sites
Belgium

Condition studied

locally advanced or metastatic ER+/HER2- breast cancer

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522331-34-00 on CTIS ↗ ← All trials in the EU